Search results
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $46.43 Average Target Price from Analysts
ETF DAILY NEWS· 2 days agoShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat ...
Earnings call: Kamada Limited reports robust Q1 2024 growth By Investing.com
Investing.com· 4 days ago(NASDAQ:KMDA), a specialty biopharmaceutical company, has reported a strong start to the year with...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of & ...
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoMalon Fakim at City of Hope. He is investigating BOT and BAL, combined with standard-of-care FOLFOX, plus bevacizumab, in first-line metastatic or...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as...
FOX 23 News Albany· 7 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
SHP report claims hospitals overcharging for oncology drugs
Winston-Salem Journal· 4 days agoThe latest commissioned report by state Treasurer Dale Folwell — released Wednesday — determined...
Q1 2024 Agenus Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoI want to highlight is the full Fox three b. regimen with Dr. Marwan for team at City of Hope he is investigating bar and bound combined with standard of care, full Fox plus bevacizumab ...
Trehalose is enabling life-changing protein therapeutics and exosomes
Nature· 6 days agoTrehalose is vital to the biopharma industry. Manufacturers of monoclonal antibodies and other protein therapeutics use this saccharide to stabilize molecules that would otherwise be degraded ...
Study: For treating retinopathy of prematurity, UB-led research proves that ranibizumab is safe
UB Reporter· 3 days agoA University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP occurs in low ...
